OPTIMISE (242114)

  https://cordis.europa.eu/project/id/242114

  FP7 (2007-2013)

  OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE)

  Optimising current therapeutic approaches to schizophrenia (HEALTH-2009-2.2.1-3)

  drug discovery  ·  schizophrenia

  2010-02-01 Start Date (YY-MM-DD)

  2016-07-31 End Date (YY-MM-DD)

  € 14,900,190 Total Cost

  Description

OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) will focus on two goals: optimising current treatments in Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, will explore the development of novel treatments and will identify potential mechanisms for new drug development. To achieve these goals we have assembled a European team of experts that is second to none in the world. Together we will pursue the following objectives: -To use MRI to optimise treatment outcome and to facilitate prediction of response to treatment; - To provide a rational basis for antipsychotic choices in the treatment of first episode schizophrenia or schizophreniform disorder; - To improve functional outcome and reduce drug discontinuation by means of psychosocial interventions. - To explore the potential of cannabidiol CBD, a modulator of endocannabinoid functioning, as an alternative to D2 based antipsychotics - To validate a new approach to improve cognitive performance in patients with cognitive deficits on the basis of their genetic make up; - To use theoretically driven neurochemical imaging (MRS) and empirically driven genetic/genomic markers as predictors of response to treatment.

  Complicit Organisations

1 Israeli organisation participates in OPTIMISE.